A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Newly Diagnosed Glioblastoma
Interventions
DRUG

TJ107

QW8

DRUG

TJ107 placebo

QW8

Trial Locations (16)

100050

Beijing Tiantan Hospital, Capital Medical University, Beijing

Unknown

Shenzhen Second People's Hospital, Shenzhen

Harbin Medical University Cancer Hospital, Harbin

Tongji Hospital, Tongji Medical College of HUST, Wuhan

Jiangsu Province Hospital, Nanjing

The Second Affiliated Hospital Of Nanchang University, Nanchang

Liaoning Cancer Hospital & Institute, Shenyang

Shengjing Hospital of China Medical University, Shenyang

General Hospital of Ningxia Medical University, Yinchuan

Tangdu Hospital of The Fourth Military Medical University of Chinese PLA, Xi'an

Peking Union Medical College Hospital, Beijing

Chongqiong Cancer Hospital, Chongqing

Huashan Hospital Affiliated to Fudan University, Shanghai

Tianjin Huanhu Hospital, Tianjin

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

TJ Biopharma Co., Ltd.

INDUSTRY